000			01565 a2200397 4500
005			20250515014410.0
264		0	_c20060413
008			200604s 0 0 eng d
022			_a0043-5341
024	7		_a10.1007/s10354-005-0245-6 _2doi
040			_aNLM _beng _cNLM
100	1		_aKöller, Marcus D
245	0	0	_aTargeted therapy in rheumatoid arthritis. _h[electronic resource]
260			_bWiener medizinische Wochenschrift (1946) _cJan 2006
300			_a53-60 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAbatacept
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntibodies, Monoclonal, Murine-Derived
650	0	4	_aAntirheumatic Agents _xtherapeutic use
650	0	4	_aArthritis, Rheumatoid _xdrug therapy
650	0	4	_aB-Lymphocytes _xdrug effects
650	0	4	_aClinical Trials as Topic
650	0	4	_aDrug Delivery Systems _xmethods
650	0	4	_aImmunoconjugates _xtherapeutic use
650	0	4	_aInterleukin-1 _xantagonists & inhibitors
650	0	4	_aInterleukin-2 _xantagonists & inhibitors
650	0	4	_aReceptors, Interleukin-6 _xantagonists & inhibitors
650	0	4	_aRituximab
650	0	4	_aSignal Transduction _xdrug effects
650	0	4	_aSynovitis _xdrug therapy
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
773	0		_tWiener medizinische Wochenschrift (1946) _gvol. 156 _gno. 1-2 _gp. 53-60
856	4	0	_uhttps://doi.org/10.1007/s10354-005-0245-6 _zAvailable from publisher's website
999			_c16078445 _d16078445